• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

369
65
48
46
19

COUNTRY

45
12
5
5
5

PRICE

296
549
1,001
1,436

PUBLISHED

104
126
494
1,436

PRODUCT TYPE

1,341
67
17
11

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Tauopathies - Pipeline Review, H1 2014

Tauopathies - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Tauopathies - Pipeline Review, H1 2014’, provides an overview of the Tauopathies’s therapeutic pipeline. This report provides...

June 2014
FROM

Japanese Encephalitis - Pipeline Review, H1 2014

Japanese Encephalitis - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Japanese Encephalitis - Pipeline Review, H1 2014’, provides an overview of the Japanese Encephalitis’s therapeutic...

June 2014
FROM

Hyperalgesia - Pipeline Review, H1 2014

Hyperalgesia - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Hyperalgesia - Pipeline Review, H1 2014’, provides an overview of the Hyperalgesia’s therapeutic pipeline. This report provides...

June 2014
FROM
Inhaled CNS Therapeutics Inhaled CNS Therapeutics - Product Thumbnail Image

Inhaled CNS Therapeutics

Neurological disorders are highly prevalent worldwide And while mental and neurological disorders are responsible for about one per cent of deaths, they account for almost 11 per cent of disease burden...

June 2014
FROM

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD...

May 2014
FROM

Amnesia Global Clinical Trials Review, H1, 2014

Amnesia Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Amnesia Global Clinical Trials Review, H1, 2014" provides data on the Amnesia clinical trial scenario. This report...

May 2014
FROM

Ataxia Global Clinical Trials Review, H1, 2014

Ataxia Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Ataxia Global Clinical Trials Review, H1, 2014" provides data on the Ataxia clinical trial scenario. This report...

May 2014
FROM

AIDS Associated Dementia Global Clinical Trials Review, H1, 2014

AIDS Associated Dementia Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “AIDS Associated Dementia Global Clinical Trials Review, H1, 2014" provides data on the AIDS Associated...

May 2014
FROM

Autism Global Clinical Trials Review, H1, 2014

Autism Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report...

May 2014
FROM

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014’, provides an overview of the...

May 2014
FROM

Ischemic Cerebral Stroke - Pipeline Review, H1 2014

Ischemic Cerebral Stroke - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Ischemic Cerebral Stroke - Pipeline Review, H1 2014’, provides an overview of the Ischemic Cerebral Stroke’s therapeutic...

May 2014
FROM

Moderate Pain - Pipeline Review, H1 2014

Moderate Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Moderate Pain - Pipeline Review, H1 2014’, provides an overview of the Moderate Pain’s therapeutic pipeline. This report...

May 2014
FROM

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2014

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2014’, provides an overview of the...

May 2014
FROM

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM
Loading Indicator

Our Clients

Our clients' logos